Cargando…

Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy—Analysis of the Phase 3 XELAVIRI Trial

INTRODUCTION: Early tumor shrinkage (ETS), depth of response (DpR), and time to DpR represent exploratory endpoints that may serve as early efficacy parameters and predictors of long-term outcome in metastatic colorectal cancer (mCRC). We analyzed these endpoints in mCRC patients treated with first-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kurreck, Annika, Heinemann, Volker, Fischer von Weikersthal, Ludwig, Decker, Thomas, Kaiser, Florian, Uhlig, Jens, Schenk, Michael, Freiberg-Richter, Jens, Peuser, Bettina, Denzlinger, Claudio, Graeven, Ullrich, Heinrich, Kathrin, Held, Swantje, Stahler, Arndt, Alig, Annabel Helga Sophie, Jelas, Ivan, von Einem, Jobst C., Stintzing, Sebastian, Giessen-Jung, Clemens, Modest, Dominik P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895369/ https://www.ncbi.nlm.nih.gov/pubmed/35251955 http://dx.doi.org/10.3389/fonc.2022.751453

Ejemplares similares

Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy
por: Alig, Annabel H. S., et al.
Publicado: (2022)

Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3
por: Fischer, Laura E., et al.
Publicado: (2022)

Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials
por: Stahler, Arndt, et al.
Publicado: (2020)

Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)
por: Heinrich, K., et al.
Publicado: (2023)

Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)
por: Modest, Dominik Paul, et al.
Publicado: (2022)

A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial
por: Giessen, Clemens, et al.
Publicado: (2011)

Frameless Single Robotic Radiosurgery for Pulmonary Metastases in Colorectal Cancer Patients
por: Von Einem, Jobst C, et al.
Publicado: (2020)

Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)
por: Modest, Dominik Paul, et al.
Publicado: (2017)

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
por: Modest, D. P., et al.
Publicado: (2016)

Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial
por: Giessen, C, et al.
Publicado: (2013)

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
por: von Einem, J. C., et al.
Publicado: (2014)

FIRE-9 – PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer
por: Raschzok, Nathanael, et al.
Publicado: (2022)

Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306
por: Modest, Dominik Paul, et al.
Publicado: (2020)

Long-term Survival in Patients Treated with a Robotic Radiosurgical Device for Liver Metastases
por: Stintzing, Sebastian, et al.
Publicado: (2019)

Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer
por: Sommerhäuser, G., et al.
Publicado: (2022)

Key Prognostic Factors Create a Composite Risk Score to Stratify Patients into High- and Low-Treatment Benefit Groups: A Multicenter, Retrospective Data Analysis of 84 Metastatic Colorectal Cancer Patients Treated with Regorafenib as Part of the CORRECT and CONSIGN Trials
por: Zöhrlaut, Linda Katharina, et al.
Publicado: (2023)

Editorial: Herpesvirus Maturation
por: Tandon, Ritesh, et al.
Publicado: (2020)

FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial
por: Heinemann, Volker, et al.
Publicado: (2020)

Integrated Analysis of the RASH Study with the Use of the “Burden of Therapy” (BOTh(®TM)) Methodology—A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic Cancer
por: Dorman, Klara, et al.
Publicado: (2023)

Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial
por: Stintzing, S, et al.
Publicado: (2011)

Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non‐interventional study MabSCale
por: Dürig, Jan, et al.
Publicado: (2022)

Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306
por: Hofmann, Felix O., et al.
Publicado: (2022)

Capecitabine-associated hand–foot–skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer
por: Hofheinz, R-D, et al.
Publicado: (2012)

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
por: Stintzing, S, et al.
Publicado: (2019)

siRNA Efficiency: Structure or Sequence—That Is the Question
por: Kurreck, Jens
Publicado: (2006)

RNA interference: Perspectives and caveats
por: Kurreck, Jens
Publicado: (2005)

Human Cytomegalovirus Uses a Host Stress Response To Balance the Elongation of Saturated/Monounsaturated and Polyunsaturated Very-Long-Chain Fatty Acids
por: Xi, Yuecheng, et al.
Publicado: (2021)

Complete Pathological Response After Neoadjuvant Short‐Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI‐H/dMMR Rectal Cancer
por: Trojan, Jörg, et al.
Publicado: (2021)

Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group
por: Hirt, Carsten, et al.
Publicado: (2021)

Survey of Long-Term Experiences of Sperm Cryopreservation in Oncological and Non-Oncological Patients: Usage and Reproductive Outcomes of a Large Monocentric Cohort
por: Lackamp, Nadine, et al.
Publicado: (2021)

Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells - TREAT-ME-1 - a phase I, first in human, first in class trial
por: von Einem, Jobst C., et al.
Publicado: (2017)

The Molecular Tweezer CLR01 Inhibits Antibody-Resistant Cell-to-Cell Spread of Human Cytomegalovirus
por: Brenner, Sina, et al.
Publicado: (2021)

Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study
por: Striefler, Jana Käthe, et al.
Publicado: (2021)

Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)
por: Kurreck, A., et al.
Publicado: (2020)

Serial Analysis of Gene Mutations and Gene Expression during First-Line Chemotherapy against Metastatic Colorectal Cancer: Identification of Potentially Actionable Targets within the Multicenter Prospective Biomarker Study REVEAL
por: Kumbrink, Jörg, et al.
Publicado: (2022)

The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer
por: Ohnmacht, Alexander J., et al.
Publicado: (2023)

Design of Small Interfering RNAs for Antiviral Applications
por: Rothe, Diana, et al.
Publicado: (2010)

Human Monocytes Are Suitable Carriers for the Delivery of Oncolytic Herpes Simplex Virus Type 1 In Vitro and in a Chicken Embryo Chorioallantoic Membrane Model of Cancer
por: Reale, Alberto, et al.
Publicado: (2023)

Quantification of Major Bacteria and Yeast Species in Kefir Consortia by Multiplex TaqMan qPCR
por: Nejati, Fatemeh, et al.
Publicado: (2020)

Generation of a Perfusable 3D Lung Cancer Model by Digital Light Processing
por: Mei, Yikun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_90hb3ggq9mm3lj80kv6i9oj699